The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

Dana-farber-cancer Institute Inc.

University of Kansas

The Broad Institute, Inc.

Rizwan Haq

David E Fisher

Frank John Schoenen

Warren S Weiner

Patrick Faloon

Robert Smith

Hans Ragnar Widlund

Cecile Marie Gstalder

The present invention is based in part on the identification of Fbxw7 as a biomarker predictive of responsiveness to anti-immune checkpoint therapies.

Biomarkers predictive of anti-immune checkpoint response

Embodiments described here are combinatorial compositions and methods using these compositions for treating melanomas having activated mutations. The compositions comprises combinations of inhibitors of a MAPK pathway, ERK inhibitors, EGFR inhibitors, oxidative phosphorylation (OXPHOS) inhibitors, inhibitors of B-Raf, mitochondrial inhibitors, c-KIT inhibitors, MEK inhibitors and tigecycline or a derivative thereof.

Combinatorial compositions and methods for treatment of melanoma

Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer. 

Inhibitors of the MITF molecular pathway

Growing community of inventors

Boston, MA, United States of America

Rizwan Haq